FluoGuide enrolls first patient in U.S. Phase 2 trial of FG001 in high-grade glioma
Copenhagen, Denmark, 5 October 2026 – FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotechnology company focused on precision cancer surgery, today announced that the first patient has been enrolled in FG001-CT-006, the Company’s U.S. Phase 2 clinical trial of FG001 in patients with newly diagnosed high-grade glioma.